安科生物参股公司PA3-17注射液新增适应症申报临床试验获得受理

Core Viewpoint - Anke Bio (300009) announced that its affiliated companies, Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd. and Boshengji Anke Cell Technology Co., Ltd., have received acceptance for a clinical trial application for PA3-17 injection targeting relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma (R/R T-ALL/LBL) [1] Group 1 - The PA3-17 injection is the world's first autologous CAR-T cell therapy product targeting CD7 that has received clinical trial approval [1] - The product was included in the list of breakthrough therapies by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in August [1]